Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

Home  /  National Uptake and Case Studies  /  Alectinib (Alecensa) as monotherapy for first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
CountryAgencyYear work was carried outLinkDetails of use
AustriaGOEG2018Dissemination to decision-makers.
AustriaHVB2018https://www.sozialversicherung.at/oeko/views/detail.xhtml?pharmaNumber=4462074 National adaptation. Made minor changes to information used. Added budget impact or cost effectiveness analysis.
AustriaLBI-HTA2018http://eprints.hta.lbg.ac.at/1152/1/DSD_HSO_Nr.77.pdf1:1 in LBI-HTA Horison Scanning in Oncology-programme.
CroatiaAAZ2018http://www.hzzo.hr/zdravstveni-sustav-rh/trazilica-za-lijekove-s-vazecih-lista/ National adaptation. Carried out translation. Added local information
FinlandHILA2018Read the report for background information. Were unable to fully utilize the report due to a different comparator. HILA also have to present our assessments in Finnish and in a specific structure.
HungaryNIPN2018Used to justify our findings in the Technology Appraisal Committee meeting
ItalyASSR RER2018Dissemination through our website: alert of publication and link to document; summary and results reported on news page
ItalyUCSC2018National adaptation. Added local information.
NorwayNOMA2018https://legemiddelverket.no/offentlig-finansiering/metodevurderinger/metodevurderingsrapporter-a National adaptation. Added local information.
PortugalINFARMED2018National adaptation. Translated report. Added local information.
SlovakiaUNIBA2018National adaptation. Added local information.
SpainAEMPS2018Cited in report as background or additional information.
SpainAETSA2018http://www.aetsa.org/publicacion/alectinib-en-primera-linea-de-tratamiento-en-pacientes-adultos-con-carcinoma-de-pulmon-no-microcitico-avanzado-alk-positivo/ National adaptation. No changes to the information. Translated into Spanish.

A summary of this assessment in Spanish together with the full English report has been published on AETSA's website for dissemination. In addition, the report has been distributed to regional decision-makers and oncologists.
SpainOSTEBA2018https://hta.lbg.ac.at/page/kontinuierliches-flash-glukosemonitoring-bei-diabetes/de
PTJA03 assessment disseminated to oncologists and relevant decision makers (managers of the Pharmacy section of the Basque Health Service).
SwedenTLV2018https://www.tlv.se/beslut/beslut-lakemedel/generell-subvention/arkiv/2018-04-26-alecensa-ingar-i-hogkostnadsskyddet.htmlNational adaptation. Added local information.
UKNICE2018https://www.nice.org.uk/guidance/indevelopment/gid-ta10206Read the assessment for background information. Used the assessment to inform the evaluation or consideration of a company submission of evidence.
UK (Scotland)SMC2018https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdfUsed the assessment to inform the evaluation or consideration of a company submission of evidence. Updated evidence.